AR123767A1 - Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii - Google Patents
Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viiiInfo
- Publication number
- AR123767A1 AR123767A1 ARP210102816A ARP210102816A AR123767A1 AR 123767 A1 AR123767 A1 AR 123767A1 AR P210102816 A ARP210102816 A AR P210102816A AR P210102816 A ARP210102816 A AR P210102816A AR 123767 A1 AR123767 A1 AR 123767A1
- Authority
- AR
- Argentina
- Prior art keywords
- expressing
- cell
- antibody
- cells
- enriching
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En la presente descripción, en ciertos aspectos, se proporcionan anticuerpos que se unen a CD8, así como células recombinantes que contienen los vectores y composiciones que comprenden los anticuerpos. También se proporcionan en la presente descripción, en ciertos aspectos, anticuerpos que se unen a CD4, así como células recombinantes que contienen los vectores, y composiciones que comprenden los anticuerpos. También se proporcionan en la presente descripción, en ciertos aspectos, anticuerpos multiespecíficos que se unen a CD4 y CD8, así como a células recombinantes que contienen los vectores, y composiciones que comprenden los anticuerpos. También se proporcionan métodos para elaborar los anticuerpos. Reivindicación 19: Un ácido nucleico que codifica el anticuerpo de una cualquiera de las reivindicaciones 1 a 18. Reivindicación 20: Un vector que comprende el ácido nucleico de la reivindicación 19. Reivindicación 21: Una célula huésped que comprende el vector de la reivindicación 20. Reivindicación 24: Una composición farmacéutica que comprende el anticuerpo de una cualquiera de las reivindicaciones 1 a 18, y un portador farmacéuticamente aceptable. Reivindicación 25: Un método para producir la composición farmacéutica de la reivindicación 24, que comprende combinar el anticuerpo con un portador farmacéuticamente aceptable para obtener la composición farmacéutica. Reivindicación 26: Un método para activar una célula T, que comprende poner en contacto la célula T con el anticuerpo de una cualquiera de las reivindicaciones 1 a 18. Reivindicación 27: Un método para enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar una célula, en donde (A) la célula es una célula que expresa CD8, en donde el método comprende: (i) proporcionar una muestra que comprende la célula que expresa CD8; poner en contacto la muestra con el anticuerpo CD8 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD8 unida al anticuerpo CD8, (ii) poner en contacto una célula que expresa CD8 con el anticuerpo CD8 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD8 unida al anticuerpo CD8, o (iii) poner en contacto una célula que expresa CD8 con el anticuerpo CD8 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD8 basado en la unión de la célula que expresa CD8 al anticuerpo CD8, en donde opcionalmente la célula que expresa CD8 es una célula T, en donde opcionalmente la célula T es un linfocito T citotóxico de CD8+ (CTL); (B) la célula es una célula que expresa CD4, en donde el método comprende: (i) proporcionar una muestra que comprende la célula que expresa CD4; poner en contacto la muestra con el anticuerpo CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD4 unida al anticuerpo CD4, (ii) poner en contacto una célula que expresa CD4 con el anticuerpo CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD4 unida al anticuerpo CD4, o (iii) poner en contacto una célula que expresa CD4 con el anticuerpo CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar la célula que expresa CD4 sobre la base de la unión de la célula que expresa CD4 al anticuerpo CD4, en donde opcionalmente la célula que expresa CD4 es una célula T, en donde opcionalmente la célula T es una célula T colaboradora de CD4+; o (C) la célula es una célula que expresa CD4 y/o una célula que expresa CD8, en donde el método comprende: (i) proporcionar una muestra que comprende las células que expresan CD4 y/o células que expresan CD8; poner en contacto la muestra con el anticuerpo multiespecífico que se une a CD8 y CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar las células que expresan CD4 y/o las células que expresan CD8 unidas al anticuerpo multiespecífico, (ii) poner en contacto las células que expresan CD4 y/o las células que expresan CD8 con el anticuerpo multiespecífico que se une a CD8 y a CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar las células que expresan CD4 y/o las células que expresan CD8 unidas al anticuerpo multiespecífico, o (iii) poner en contacto las células que expresan CD4 y/o las células que expresan CD8 con el anticuerpo multiespecífico que se une a CD8 y a CD4 de una cualquiera de las reivindicaciones 1 a 18; y enriquecer, aislar, separar, purificar, clasificar, seleccionar, capturar o detectar las células que expresan CD4 y/o las células que expresan CD8 basado en la unión de las células que expresan CD4 y/o las células que expresan CD8 al anticuerpo multiespecífico, en donde opcionalmente las células que expresan CD4 y/o células que expresan CD8 son células T, en donde opcionalmente las células que expresan CD4 son células T colaboradoras de CD4+, en donde opcionalmente las células que expresan CD8 son CTL de CD8+.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091078P | 2020-10-13 | 2020-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123767A1 true AR123767A1 (es) | 2023-01-11 |
Family
ID=81078725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102816A AR123767A1 (es) | 2020-10-13 | 2021-10-12 | Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11926667B2 (es) |
| EP (1) | EP4228693A4 (es) |
| JP (1) | JP2023544890A (es) |
| KR (1) | KR20230086765A (es) |
| CN (1) | CN116635052A (es) |
| AR (1) | AR123767A1 (es) |
| CA (1) | CA3198590A1 (es) |
| TW (1) | TW202231292A (es) |
| UY (1) | UY39467A (es) |
| WO (1) | WO2022081516A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR123767A1 (es) * | 2020-10-13 | 2023-01-11 | Janssen Biotech Inc | Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii |
| EP4232071A4 (en) | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| KR20240024829A (ko) | 2021-05-19 | 2024-02-26 | 애셔 바이오테라퓨틱스, 인크. | Il-21 폴리펩타이드 및 표적화된 작제물 |
| EP4514843A1 (en) * | 2022-04-26 | 2025-03-05 | K-Bio Investment, LLC | Formulation for antigen-binding molecules that bind to porphyromonas gingivalis |
| CN119546343A (zh) * | 2022-04-27 | 2025-02-28 | 亚设生物治疗公司 | 细胞因子融合蛋白与cd8抗原结合分子的组合 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| CN117736299B (zh) * | 2023-12-20 | 2025-12-19 | 杭州斯达特生物科技有限公司 | 重组人源CD8α蛋白及其制备方法与应用 |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US6011146A (en) | 1991-11-15 | 2000-01-04 | Institut Pasteur | Altered major histocompatibility complex (MHC) determinant and methods of using the determinant |
| US5734023A (en) | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5820866A (en) | 1994-03-04 | 1998-10-13 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for T cell regulation |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869270A (en) | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| ATE423789T1 (de) | 1997-09-16 | 2009-03-15 | Univ Oregon Health & Science | Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen |
| GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| US6232445B1 (en) | 1997-10-29 | 2001-05-15 | Sunol Molecular Corporation | Soluble MHC complexes and methods of use thereof |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| AU2004253738A1 (en) | 2003-07-01 | 2005-01-13 | Ucb Pharma S.A. | Modified antibody Fab fragments |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| WO2008020827A2 (en) | 2005-08-01 | 2008-02-21 | Biogen Idec Ma Inc. | Altered polypeptides, immunoconjugates thereof, and methods related thereto |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| WO2010045340A1 (en) | 2008-10-14 | 2010-04-22 | Centocor Ortho Biotech Inc. | Methods of humanizing and affinity-maturing antibodies |
| SI2393828T1 (sl) | 2009-02-03 | 2017-01-31 | Amunix Operating Inc. | Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| SG190006A1 (en) * | 2010-11-04 | 2013-06-28 | Boehringer Ingelheim Int | Anti-il-23 antibodies |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| HUE044633T2 (hu) | 2011-10-27 | 2019-11-28 | Genmab As | Heterodimer fehérjék elõállítása |
| AU2012332021B8 (en) | 2011-11-04 | 2017-10-12 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| HRP20201004T1 (hr) | 2011-12-20 | 2020-10-16 | Medimmune, Llc | Modificirani polipeptidi za skelete bispecifičnog protutijela |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| EP2925348B1 (en) | 2012-11-28 | 2019-03-06 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
| US10077298B2 (en) | 2012-11-28 | 2018-09-18 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| EP2968520B1 (en) | 2013-03-14 | 2021-05-12 | MacroGenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
| PL3587448T3 (pl) | 2013-03-15 | 2021-11-29 | Xencor, Inc. | Białka heterodimeryczne |
| EP2970435B1 (en) | 2013-03-15 | 2020-08-12 | Eli Lilly and Company | Methods for producing fabs and bi-specific antibodies |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| JP2016512029A (ja) | 2013-03-15 | 2016-04-25 | ヤンセン バイオテツク，インコーポレーテツド | 遺伝子組換えタンパク質中のｃ末端リジン、ガラクトース、及びシアル酸含量を制御する製造方法 |
| TWI742423B (zh) | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
| WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
| BR112018014368A2 (pt) | 2016-01-13 | 2019-02-05 | Compass Therapeutics Llc | polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, conjugado, composição farmacêutica, método para tratar um indivíduo com câncer, método para inibir ou reduzir o crescimento de câncer, composição, célula, método de fazer um polipeptídeo de construto de ligação ao antígeno imunomodulador multiespecífico, vetor ou conjunto de vetores e kit |
| DK3411398T3 (da) * | 2016-02-05 | 2024-06-24 | Orionis Biosciences BV | Målrettede terapeutiske midler og anvendelse heraf |
| CN109310739A (zh) | 2016-03-31 | 2019-02-05 | 内恩疗法公司 | 新抗原及其使用方法 |
| WO2017177207A1 (en) | 2016-04-07 | 2017-10-12 | Bostongene, Llc | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
| WO2017213695A1 (en) | 2016-06-07 | 2017-12-14 | The Brigham And Women's Hospital, Inc. | Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions |
| JP7022123B2 (ja) | 2016-09-30 | 2022-02-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｃｄ３に対する二重特異性抗体 |
| WO2018170096A1 (en) * | 2017-03-14 | 2018-09-20 | Dualogics, Llc | Use of a cd4/cd8 bispecific antibody for the treatment of diabetes |
| WO2018199318A1 (ja) * | 2017-04-28 | 2018-11-01 | 国立大学法人高知大学 | 抗ｇｐｃ－１抗体 |
| IL316355A (en) * | 2017-07-24 | 2024-12-01 | Regeneron Pharma | Anti-CD8 antibodies and their uses |
| CN111295394B (zh) | 2017-08-11 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 抗cd8抗体及其用途 |
| RU2020135920A (ru) | 2018-04-05 | 2022-05-05 | Новартис Аг | Триспецифические связывающие молекулы против форм рака и пути их применения |
| WO2019200022A1 (en) | 2018-04-11 | 2019-10-17 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
| MA52772A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations |
| WO2020060924A1 (en) * | 2018-09-17 | 2020-03-26 | Dualogics, Llc | Use of a cd4/cd8 bispecific antibody for the treatment of autoimmune/inflammatory disorders |
| US20210214440A1 (en) | 2019-12-18 | 2021-07-15 | Janssen Biotech, Inc. | Materials and methods for in vivo biological targeting |
| AR123767A1 (es) * | 2020-10-13 | 2023-01-11 | Janssen Biotech Inc | Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii |
-
2021
- 2021-10-12 AR ARP210102816A patent/AR123767A1/es unknown
- 2021-10-12 TW TW110137861A patent/TW202231292A/zh unknown
- 2021-10-12 EP EP21880872.3A patent/EP4228693A4/en active Pending
- 2021-10-12 US US17/499,597 patent/US11926667B2/en active Active
- 2021-10-12 KR KR1020237016271A patent/KR20230086765A/ko active Pending
- 2021-10-12 CA CA3198590A patent/CA3198590A1/en active Pending
- 2021-10-12 JP JP2023522415A patent/JP2023544890A/ja active Pending
- 2021-10-12 WO PCT/US2021/054487 patent/WO2022081516A1/en not_active Ceased
- 2021-10-12 CN CN202180083729.8A patent/CN116635052A/zh active Pending
- 2021-10-12 UY UY0001039467A patent/UY39467A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3198590A1 (en) | 2022-04-21 |
| UY39467A (es) | 2022-04-29 |
| US20220112288A1 (en) | 2022-04-14 |
| KR20230086765A (ko) | 2023-06-15 |
| US11926667B2 (en) | 2024-03-12 |
| EP4228693A4 (en) | 2024-12-18 |
| TW202231292A (zh) | 2022-08-16 |
| JP2023544890A (ja) | 2023-10-25 |
| CN116635052A (zh) | 2023-08-22 |
| WO2022081516A1 (en) | 2022-04-21 |
| EP4228693A1 (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123767A1 (es) | Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii | |
| AU2023248053B2 (en) | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same | |
| Trzonkowski et al. | First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127− T regulatory cells | |
| US12195724B2 (en) | Methods of producing T cell populations enriched for stable regulatory T-cells | |
| RU2020133435A (ru) | Способ инкубирования популяции клеток и реагент для мультимеризации | |
| RU2016145424A (ru) | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии | |
| RU2577702C2 (ru) | 3d-facs-анализ-adcc nk-клеток | |
| WO2017178572A1 (en) | Ex vivo bite-activated t cells | |
| US10316291B2 (en) | Immuno-oncology mesodermal progenitor (ioMP) cell | |
| AR123935A1 (es) | COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g | |
| Yoshino et al. | Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using anti-human cross-reactive antibodies | |
| US10758568B2 (en) | Regulatory T-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract | |
| US20170038395A1 (en) | Cd8+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases | |
| US20170038394A1 (en) | Method for the identification of cd4+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases | |
| AR122496A1 (es) | Métodos para preparar vesículas extracelulares y usos de estas | |
| McMurchy et al. | In vitro generation of human T regulatory cells: generation, culture, and analysis of FOXP3-transduced T cells | |
| EP3509631B1 (en) | In vitro propagation of babesia microti | |
| Iwaszkiewicz-Grzes et al. | Antigen-reactive regulatory T cells can be expanded in vitro with monocytes and anti-CD28 and anti-CD154 antibodies | |
| Ito et al. | High-throughput cloning reveals diverse properties of T-cell receptors targeting minor histocompatibility antigens | |
| WO2022120240A1 (en) | Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells | |
| AR124013A1 (es) | Proteínas de unión que reconocen al antígeno ha-1 y usos de las mismas | |
| Dustin | A wish-list for modeling immunological synapses | |
| CN120554482A (zh) | 一种具有流感病毒血凝素蛋白特异性识别功能的γδT细胞受体及其应用 | |
| der Meijden et al. | 4HLA-DPB1 mismatching results in the generation of | |
| NZ727479A (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |